CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Nivolumab (Opdivo) and Ipilimumab (Yervoy) - Details

Project Number pCODR 10229
Brand Name Opdivo and Yervoy
Generic Name Nivolumab and Ipilimumab
Tumour Type Lung
Indication Malignant Pleural Mesothelioma (MPM)
Funding Request OPDIVO, in combination with ipilimumab for the first-line treatment of patients with unresectable malignant pleural mesothelioma.
Review Status Pending
Pre Noc Submission Yes
NOC Date
Manufacturer Bristol-Myers Squibb Canada
Sponsor Bristol-Myers Squibb Canada
Submission Date (Target Date) October 29, 2020
Submission Type New Indication
Prioritization Requested
Stakeholder Input Deadline (target date based on target submission date) ‡ November 12, 2020
Check-point meeting (target date)
pERC Meeting (target date)
Initial Recommendation Issued (target date)
Feedback Deadline (target date) ‡
pERC Reconsideration Meeting (target date)
Final Recommendation Issued (target date)
Notification to Implement Issued

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.